Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1649989 · FYE Sep 30 · Prices AT CLOSE 2026-08-19 (USD) Last $0.69 · Day −1.41% · Mkt cap $170M · 1Y −73.8% · Off 52W high −79.6% · Vol (1Y) 170.0% Price2023-08-21 → 2026-08-19 OTLK close: $27.4 on 2023-08-21 to $0.7 on 2026-08-19. Split-adj closes · 240 of 2,536 · price returnⓘ At a glance | Short interest8.2% of sh out | | Days to cover1.1d | | 13F net flow (QoQ)+0.40% | | Top-10 13F concentration86.2% | | Next report (est.)2026-11-13 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Sales (TTM)$1.4M | | Earnings (TTM)-$61.1M | | Net margin−4416.2% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−56.3% | | 1Y−73.8% | | 3Y−97.5% | | 5Y−98.4% | | 10Y−99.9% | | Since incept. (ann.)−48.5% |
Total return · from 2016-07-11ⓘ Risk | Ann. volatility (1Y)170.0% | | Ann. volatility (3Y)145.2% | | Sharpe (1Y)0.11 | | Sharpe (3Y)0.08 | | Max drawdown (1Y)−93.3% | | Max drawdown (3Y)−99.3% | | Beta (3Y vs SPY)0.43 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| ARMISTICE CAPITAL, LLC | 4.2M | $857,774 | 5.02% | new | | VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | $405,235 | 2.37% | new | | GEODE CAPITAL MANAGEMENT, LLC | 603,606 | $124,235 | 0.73% | +90.7% | | GILPIN WEALTH MANAGEMENT, LLC | 600,162 | $123,514 | 0.72% | +69.4% | | BlackRock, Inc. | 477,471 | $98,264 | 0.57% | +18.0% | | COMMONWEALTH EQUITY SERVICES, LLC | 470,000 | $96,730 | 0.57% | +317.8% | | Warberg Asset Management LLC | 275,000 | $56,375 | 0.33% | new | | RENAISSANCE TECHNOLOGIES LLC | 255,157 | $52,511 | 0.31% | new |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-08-14 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-06-30 | 2026-08-14 | −$0.15 | — | — | — | | 2026-03-31 | 2026-05-13 | −$0.05 | — | — | — | | 2025-12-31 | 2026-02-17 | −$0.38 | −152.8% | — | — | | 2025-06-30 | 2025-08-14 | −$0.55 | — | $1.5M | — |
As-reported XBRL · next 2026-11-13 est.ⓘ Segment mixFY2025 (ended Sep 2025) Development And Commercialization Of Ons5010Or Lytenava 100% business · TAGGED revenueⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
|
